A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
Saved in:
| Title: | A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. |
|---|---|
| Authors: | Masarova L; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Reeves BN; Division of Hematology, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., El Chaer F; Division of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, United States., Foltz L; Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Tashi T; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States., Abu-Zeinah G; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States., Lucas J; Medical Oncology and Hematology, Marin Cancer Care, Greenbrae, CA, United States., Halpern AB; University of Washington Medical Center, Seattle, WA, United States., Maze D; Princess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada., Qin A; PharmaEssentia Corporation, Taipei, Taiwan., Safah H; Our Lady of the Lake Medical Center, Baton Rouge, LA, United States., Lan F; Stony Brook University Medical Center, Stony Brook, NY, United States., O'Connell CL; Keck School of Medicine, University of Southern California, Los Angeles, CA, United States., Goel S; Department of Hematology and Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, United States., Rein L; Department of Medicine, Duke University School of Medicine, Durham, NC, United States., Fang B; Astera Cancer Care, East Brunswick, NJ, United States., How J; Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, MA, United States., Babu S; Fort Wayne Medical Oncology & Hematology, Fort Wayne, IN, United States., Li Z; Greater Baltimore Medical Center, Baltimore, MD, United States., Cerquozzi S; Division of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada., Oh ST; Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States., Hunter AM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States., Podoltsev N; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States., Vachhani P; O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, United States., Yacoub A; Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas, MO, United States., Cunningham JM; Division of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, United States., Hillis C; Department of Oncology, McMaster University, Hamilton, ON, Canada., Otoukesh S; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States., Zagrijtschuk O; PharmaEssentia USA, Burlington, MA, United States., Castro H; Everest Clinical Research, Markham, ON, Canada., Bose P; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. |
| Source: | Frontiers in medicine [Front Med (Lausanne)] 2025 Apr 17; Vol. 12, pp. 1548590. Date of Electronic Publication: 2025 Apr 17 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
